Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation

Journal of Tropical Pediatrics

Volumn 59, Issue 2, 2013, Pages 90-94

  Liwa, A C ^a   Schaaf, H S ^a   Rosenkranz, B ^a   Seifart, H I ^a   Diacon, A H ^a   Donald, P R ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Children; Para aminosalicylic acid; Pharmacokinetics

Indexed keywords

AMINOSALICYLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGE FACTORS; AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOUTH AFRICA; TANDEM MASS SPECTROMETRY; TUBERCULOSIS; YOUNG ADULT;

EID: 84875772699     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fms053     Document Type: Article

References (21)

1. Lehman J. Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis 1964;90:953-6.
2. Sõderjelm L. Serum para-aminosalicylic acid (PAS) following oral ingestion in children. Tex Rep Biol Med 1949;7:471-9.
3. Getahun H, Gunneberg C, Granich R, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010;50(Suppl. 3):S201-7.
4. World Health Organization. Guidelines for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization (WHO/HTM/TB/2006.371), 2006.
5. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Ann Rev Pharmacol Toxicol 2008;48:303-32.
6. Schaaf HS, Parkin DP, Seifart H1, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90:614-8.
7. Donald PR, Maritz JS, Diacon AH. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis 2011;91:196-207.
8. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb) 2012;92:1-8.
9. Goldman JL, Kearns GL, Abdel-Rahman SM. Pharmacological considerations of antitubercular agents in children. In: Donald PR, and van Helden PD (eds). Antituberculosis Chemotherapy; Prog Resp Research. Vol. 40. Basel: Karger, 2011, 161-75.
10. Cynamon MH, Zhang Y, Harpster T, et al. High-dose isoniazid therapy for isoniazid-resistant Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999;43:2922-4.
11. Katiyar SK, Bihari S, Prakash S, et al. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45.
12. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross- and co-resistance in children with isoniazidresistant tuberculosis. Int J Tuberc Lung Dis 2009;13: 1355-9.
13. Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994;14:40-6.
14. Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999;159:932-4.
15. Maggioni G, Assensio AM. Alcune osservazioni sulle concentrazioni del PAS nei liquidi orhanici del bambino. Archiv Ital di Pediatr Puericol 1950;14:85-100.
16. Bridge EV, Carr DT. Clinical use of a single daily dose of para-aminosalicylic acid in association with isoniazid. Am Rev Tuberc 1958;78:749-52.
17. Riska N, Tennberg C. Optimal PAS dosage. Am Rev Tuberc 1962;86:430-3.
18. Lehman J. The role of the metabolism of P-aminosalicylic acid (PAS) in the treatment of tuberculosis. Scand J Respir Dis 1969;50:169-85.
19. Karlson AG, Carr DT. Effect of single and of double daily doses of para-aminosalicylic acid in tuberculosis of guinea pigs. Am Rev Tuberc 1958;78:753-9.
20. Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
21. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. Br Med J 1952;1:1157-62.